"Más nos conoce, más nos prescribe"
"Novedades Euroderm"  
» Home | » Novedades
MRSA Most Common Cause of Skin Infections in Patients Presenting in ERs - 08/17/2006 03:41:08 PM »
LOS ANGELES, CA -- August 17, 2006 -- Think that's a spider bite on your arm? Think again. It could be methicillin-resistant Staphylococcus aureus, or MRSA, a type of staph infection increasingly seen in communities across the nation that is resistant to antibiotics most commonly used to treat skin infections....
FDA Expands Remicade(R) Psoriatic Arthritis Indication: Anti-TNF Shown to Inhibit Joint Damage and Improve Physical Function / 08/14/2006 09:02:44 AM »
HORSHAM, PA -- August 14, 2006 -- Centocor, Inc. announced today that the U.S. Food and Drug Administration (FDA) has extended its approval for Remicade(R) (infliximab) for inhibiting progression of structural damage and improving physical function in patients with psoriatic...
Biologic Enbrel(R) (Entanercept) Available in Easy-to-Use, Prefilled Syringe - 08/10/2006 09:58:47 AM »

MISSISSAUGA, CANADA -- August 10, 2006 -- Biologic therapy Enbrel® (entanercept), used in the treatment of various forms of arthritis and moderate to severe plaque psoriasis, is now available in a new, easy-to-use prefilled syringe, eliminating...

Fuente del Material: PSLGroup
Línea directa Ceo
Línea directa Ceo
Synera, a New Topical Anesthetic Patch Developed by ZARS Pharma, is Launched / 06/20/2006 01:34:54 PM
SALT LAKE CITY, UT -- June 20, 2006 -- ZARS Pharma announced that Endo Pharmaceuticals Inc. launched Synera(TM) in the United States (lidocaine 70mg and tetracaine 70mg). Synera is the first topical patch approved for the prevention of pain associated with superficial venous access and superficial dermatological procedures in patients 4 months of age and older. Endo is marketing the Synera patch through its existing 70-person hospital sales force. ZARS Pharma licensed the North American sales and marketing rights to Endo earlier this year.
Fuente del Material: PSLGroup | Ampliar nota.
Study Reports Significant Malignant Melanoma Survival Results With Natural Human Alpha Interferon / 06/20/2006 01:29:34 PM
PLANTATION, FL -- June 20, 2006 -- Viragen, Inc. and its majority-owned subsidiary, Viragen International, Inc., today announced that Acta Oncologica, a leading European journal in clinical oncology, has published an article profiling the use of Multiferon (natural human alpha interferon) for the adjuvant treatment of high-risk (Stages IIb-III) malignant melanoma patients (Volume 45, Number 4, June 2006, pp.389-399).
Fuente del Material: PSLGroup | Ampliar nota.
Oxxon Therapeutics' Hi-8(TM) MEL Therapeutic Vaccine Demonstrates Potential for Treatment of Advanced Metastatic Melanoma / 06/16/2006 03:51:37 PM
Clinical Efficacy Data Presented at 42nd Annual ASCO Meeting - ATLANTA, GA, and OXFORD, UK -- June 16, 2006 -- Oxxon Therapeutics today presents data from its phase 2 clinical study of its novel Hi-8(TM) MEL therapeutic vaccine in patients with advanced non-resectable melanoma, at the 42nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Atlanta, GA.
Fuente del Material: PSLGroup | Ampliar nota.
Información Legal | Privacidad y seguridad | Contactos | Accesibilidad | Site Map
Todos los derechos reservados © Euroderm Laboratorios 2006 - All rights reserved.